drugset / Trial / NCT02662764
Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg
NaSingle-groupOpen-labelTreatment
Summary
Study to evaluate the overall performance of the Zalviso System™ (sufentanil sublingual tablet system) 15 mcg
Timeline
- Start
- 2016-09-28
- Primary completion
- 2017-04-14
- Completion
- 2017-05-05
Outcome
Met primary endpoint
release “Reported successful outcome of ZALVISO Phase 3 IAP312 study on device functionality, achieving the study objective with 2.2% of patients experiencing a device error” talphera.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sufentanil | Other / unclassified | 15 ug | Other |
Indications
No indication recorded.